Boesen EI. Chronic elevation of IL-1␤ induces diuresis via a cyclooxygenase 2-mediated mechanism. Am J Physiol Renal Physiol 305: F189 -F198, 2013. First published May 8, 2013 doi:10.1152/ajprenal.00075.2013.-Chronic renal inflammation is an increasingly recognized phenomenon in multiple disease states, but the impact of specific cytokines on renal function is unclear. Previously, we found that 14-day interleukin-1␤ (IL-1␤) infusion increased urine flow in mice. To determine the mechanism by which this occurs, the current study tested the possible involvement of three classical prodiuretic pathways. Chronic IL-1␤ infusion significantly increased urine flow (6.5 Ϯ 1 ml/day at day 14 vs. 2.3 Ϯ 0.3 ml/day in vehicle group; P Ͻ 0.05) and expression of cyclooxygenase (COX)-2, all three nitric oxide synthase (NOS) isoforms, and endothelin (ET)-1 in the kidney (P Ͻ 0.05 in all cases). Urinary prostaglandin E metabolite (PGEM) excretion was also significantly increased at day 14 of IL-1␤ infusion (1.21 Ϯ 0.26 vs. 0.29 Ϯ 0.06 ng/day in vehicle-infused mice; P ϭ 0.001). The selective COX-2 inhibitor celecoxib markedly attenuated urinary PGEM excretion and abolished the diuretic response to chronic IL-1␤ infusion. In contrast, deletion of NOS3, or inhibition of NOS1 with L-VNIO, did not blunt the diuretic effect of IL-1␤, nor did pharmacological blockade of endothelin ETA and ETB receptors with A-182086. Consistent with a primary effect on water transport, IL-1␤ infusion markedly reduced inner medullary aquaporin-2 expression (P Ͻ 0.05) and did not alter urinary Na ϩ or K ϩ excretion. These data indicate a critical role for COX-2 in mediating the effects of chronic IL-1␤ elevation on the kidney.
CHRONIC INFLAMMATION IS NOW a recognized hallmark of chronic kidney disease and many pathological conditions associated with renal injury, including diabetes, hypertension, and autoimmune/autoinflammatory diseases. Inflammatory cytokines exert multifaceted but as yet incompletely understood effects on the kidney. In addition to driving injurious processes such as renal fibrosis (24) , inflammatory cytokines have also been shown acutely or in vitro to stimulate production of vasoactive substances, and can affect tubular transport processes. However, little is currently known regarding the long-term effects of specific cytokines on renal function, or the mechanisms by which they act in a chronic setting.
Interleukin-1␤ (IL-1␤) is a proinflammatory cytokine produced by macrophages and other cells of the monocytic lineage, but also by endothelial cells (52) , tubular epithelial cells (53) , and renal mesangial cells (27) . Increased levels of IL-1␤ in the kidney have been reported in several pathological conditions, including renal ischemia-reperfusion injury (47) , ureteral obstruction (59) , endotoxemia (11, 60) , glomerulonephritis (49) , and diabetes (29) . Although it has been shown that anti-IL-1 therapies or deletion of IL-1␤ or its receptors have renoprotective effects in several of these conditions (14, 25, 51, 59) , the effect of chronically elevated IL-1␤ on renal function as opposed to injury is unclear. Previously, we found that mice chronically administered IL-1␤ display marked increases in renal IL-1␤ levels, accompanied by increases in urine flow (6) . Interestingly, diuresis/polyuria and defects in urinary concentrating ability occur subsequent to several of the above pathological conditions including acute kidney injury (4), endotoxemia (47) , and following acute ureteral obstruction (63) , although the mechanisms are incompletely understood. Therefore, the aim of the current study was to determine the mechanism by which chronic elevation of IL-1␤ induces a diuretic response, with experiments testing the involvement of three classical prodiuretic factors: endothelin-1 (ET-1) (21), prostaglandins (13) , and nitric oxide (NO) (30) .
METHODS
All animal experiments were performed at Georgia Health Sciences University, Augusta, GA and the procedures were approved in advance by the Institutional Animal Care and Use Committee. Experiments were performed on male C57BL/6 mice, and in one experiment also on NO synthase isoform 3-null (NOS3 Ϫ/Ϫ ) mice on a C57BL/6 background (all from Jackson Laboratories, Bar Harbor, ME). Mice were housed individually and maintained on a normal-salt diet (0.3% sodium; Harlan Teklad, Madison, WI) and tap water. In some experiments, mice were treated with 1) the combined endothelin ETA and ETB receptor antagonist A-182086 (57) (30 mg·kg Ϫ1 ·day Ϫ1 ; kindly provided by Abbott Laboratories, Abbott Park, IL) or vehicle (2 ml/kg sugar-free pudding); 2) the selective cyclooxygenase (COX)-2 inhibitor celecoxib (36) (30 mg·kg Ϫ1 ·day Ϫ1 ; Pfizer, Mission, KS) or vehicle (as above); 3) the selective NOS1 inhibitor N 5 -(1-imino-3-butenyl)-L-ornithine (3) (L-VNIO; 100 mg·kg Ϫ1 ·day Ϫ1 in drinking water; Cayman Chemicals, Ann Arbor, MI) or regular tap water. Drug treatments commenced 3 days before subcutaneous implantation of micro-osmotic pumps (Alzet 1002, DURECT, Cupertino, CA; implanted under 2% isoflurane anesthesia, Baxter Healthcare, Deerfield, IL) to deliver mouse recombinant IL-1␤ (10 ng/h; R&D Systems, Minneapolis, MN) or vehicle (phosphate-buffered saline containing 0.1% bovine serum albumin) for 14 days. At the end of the 2-wk infusion period, mice were placed in metabolic cages (Lab Products, Seaford, DE) for 24 h for urine collection. During this period, mice were given a single 8-g portion of gel diet containing 0.3% sodium to avoid interference with urine collection by spilled solid food (Micro stabilized Rodent Liquid Diet, TestDiet, Richmond, IN, with 7% agar and NaCl added to give a final concentration of 0.3% sodium). The mice consistently ate all gel provided and in addition had free access to drinking water during this time. After mice were removed from metabolic cages at the end of the 2-wk IL-1␤ or vehicle infusion, the mice were anesthetized (pentobarbital sodium at 60 mg/kg, Abbott, North Chicago, IL), a terminal blood sample was taken by cardiac puncture, centrifuged at 4°C, and the plasma was collected. Kidneys from IL-1␤-and vehicle-infused mice were dissected into cortex, outer and inner medulla. Plasma, renal tissue, and urine samples were snap-frozen in liquid nitrogen and stored at Ϫ80°C until analyzed. Kidneys from a small number of additional vehicle-or IL-1␤-infused mice were fixed with 10% neutral buffered formalin, embedded in paraffin, and COX-2 immunoreactivity was detected in sections following incubation with an anti-COX-2 antibody (ab15191, Abcam, Cambridge, MA). Images were captured using a Digital Sight DS-5M-L1 system (Nikon, Melville, NY) fitted to an Axioskop 20 light microscope (Carl Zeiss, Thornwood, NY), and brightness and contrast were adjusted using Microsoft PowerPoint 2010.
Sample analysis. Expression levels of ET-1, COX-1, COX-2, NOS1, NOS2, and NOS3 mRNA in the kidney were assessed by quantitative RT-PCR with GAPDH serving as a control, as previously described (6) using commercially available primers (QuantiTect Primer Assays, Qiagen, Valencia, CA). For Western blot analysis, outer or inner medullary tissues were homogenized in a pH 7.4 buffer containing 50 mM Tris, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% ␤-mercaptoethanol, 10% glycerol plus protease inhibitors (1 mM PMSF, 2 M leupeptin, 1 M pepstatin A, 1:1,000 dilution of 0.1% aprotinin). Samples were centrifuged at 10,000 rpm for 5 min and 50 g of outer medullary protein [for the Na-K-2Cl cotransporter (NKCC2)] or 5 g inner medullary protein [for aquaporin-2 (AQP-2)] solubilized in Laemmli sample buffer at 60°C for 15 min and separated by SDS-PAGE (7.5 and 12% gels, respectively). Gels were then transferred to PVDF membranes and incubated overnight at 4°C with primary antibodies for NKCC2 (AB3562P at 1:1,000, EMD Millipore, Billerica, MA) or AQP-2 (sc-9882 at 1:2,500, Santa Cruz Biotechnology, Dallas, TX). ␤-Actin was used as a loading control (A1978 at 1:5,000, Sigma, St. Louis, MO). Immunoreactivity was visualized and quantified by densitometry using a Li-Cor Odyssey infrared imaging system (LiCor Biosciences, Lincoln, NE) and fluorescently tagged secondary antibodies (Rockland Immunochemical, Gilbertsville, PA and Li-Cor Biosciences for IRDYE800 conjugates; Molecular Probes, Grand Island, NY for Alexa Fluor 680 conjugates). Plasma IL-1␤ concentrations were measured by ELISA (R&D Systems). Plasma levels of other cytokines and inflammatory markers were assessed by antibody array (Proteome Profiler Mouse Cytokine Array Panel A, R&D Systems). Urinary Na ϩ and K ϩ concentrations were measured by ion-sensitive electrode (EasyLyte Analyzer, Medica, Bedford, MA). Urinary and plasma osmolalities were measured using a Wescor 5500 Vapor Pressure Osmometer (Wescor, Logan, UT). Prostaglandin E metabolites were measured in urine via enzymatic immunoassay (Cayman Chemical). Urinary nitrite and nitrate (NO x) excretion was measured by an HPLC-based method (ENO-20 NOx Analyzer, EiCOM, San Diego, CA).
Statistical analysis. Data are expressed as means Ϯ SE and were analyzed by unpaired t-test or two-factor ANOVA followed by Bonferroni post hoc test where appropriate using Prism 5 for Mac OSX, version 5.0c (GraphPad Software, San Diego, CA).
RESULTS
In our previous study, chronic IL-1␤ infusion was found to enhance renal and circulating levels of the prodiuretic factor ET-1 (6) . Accordingly, the effect of combined endothelin ET A and ET B receptor antagonism on the diuretic response to chronic IL-1␤ was tested. Infusion of IL-1␤ subcutaneously for 14 days produced a marked elevation of plasma IL-1␤ in mice receiving IL-1␤ alone (165 Ϯ 10 pg/ml; n ϭ 5) or with simultaneous treatment with the combined ET A and ET B receptor antagonist A-182086 (164 Ϯ 28 pg/ml; n ϭ 6), whereas plasma IL-1␤ was below detection (Ͻ7 pg/ml) in all eight vehicle-treated mice not receiving A-182086 (n ϭ 8), and below detection except in all except one (10 pg/ml) out of six vehicle-infused mice receiving A-182086. IL-1␤ infusion induced a significant increase in urine flow (Fig. 1A ) that was not blunted by treatment with A-182086 (P Antagonist ϭ 0.5). Urinary Na ϩ excretion was not significantly increased by IL-1␤ infusion, although treatment with A-182086 produced a significant decrease in Na ϩ excretion in vehicle-and IL-1␤-infused mice (P Antagonist Ͻ 0.01; Fig. 1B ). Plasma ET-1 concentration was increased three-to fourfold in mice treated with A-182086 compared with vehicle-treated mice, consistent with successful endothelin receptor blockade (data not shown). Quantitative RT-PCR confirmed that IL-1␤ infusion significantly increased ET-1 mRNA levels in renal cortex, outer and inner medulla (P Infusion Ͻ 0.001 in all cases; Fig. 2 ) and that this was not significantly altered by A-182086 treatment except for a small but statistically significant increase in the inner medulla (P Antagonist ϭ 0.05; Fig. 2C ). These data indicate that ET-1 does not mediate the diuretic effect of chronic elevation of IL-1␤.
IL-1 has been shown to stimulate collecting duct prostaglandin E 2 production (19) and to acutely induce diuresis and natriuresis (20) . As a first step toward determining whether chronic elevation of IL-1␤ stimulated diuresis via prostanoids, prostaglandin E metabolites (PGEM) were measured in the urine of vehicle-and IL-1␤-infused mice, with IL-1␤ infusion inducing a significant increase in PGEM excretion at day 14 compared with vehicle infusion (P ϭ 0.001; Fig. 3 ). To further dissect the molecular mechanism involved, mRNA levels of COX-1 and COX-2, which are the rate-limiting enzymes in prostanoid production, were measured in the kidney of vehicle-and IL-1␤-infused mice (Fig. 4) . Infusion of IL-1␤ for 14 days produced a small but statistically mice underwent IL-1␤ or vehicle infusion, with and without treatment with the selective COX-2 inhibitor celecoxib. COX-2 inhibition abolished the diuretic response (Fig. 6A) and rise in PGEM excretion (Fig. 6E) . The increase in water intake ( Fig. 6B ) and decrease in urine osmolality observed in IL-1␤-infused mice (Fig. 6F) were also abolished by COX-2 inhibition. There were no significant differences in urinary osmolar excretion, Na ϩ excretion, or K ϩ excretion between the four groups (Fig. 6) . Plasma osmolality was not significantly different between vehicle-and IL-1␤-infused mice (data not shown). These data provide compelling evidence that COX-2-mediated prostanoid production plays a dominant role in mediating the diuretic response to chronic IL-1␤ infusion.
Following on from the observed changes in urine flow and urine osmolality, expression of AQP-2 in inner medullary tissue was compared between IL-1␤-and vehicle-infused mice. As shown in Fig. 7 , Western blot analysis of inner medullary tissue revealed an ϳ45% reduction in levels of both glycosylated (Fig. 7A ) and nonglycosylated AQP-2 (43) (Fig. 7B ) of IL-1␤-infused mice compared with vehicle-infused mice (P Ͻ 0.05 in both cases). Consistent with the lack of change observed in urinary Na ϩ and K ϩ excretion rates (Fig. 6 ), IL-1␤ infusion did not alter outer medullary NKCC2 protein expression (Fig. 7C) .
NO is another potential mediator of the effects of both IL-1␤ (55) and ET-1 in the kidney. Accordingly, mRNA levels of all three NOS isoforms were measured in renal tissue from vehicle-and IL-1␤-infused mice, with and without treatment with A-182086. As shown in Fig. 8 , both NOS1 (also known as neuronal NOS) and NOS3 (also known as endothelial NOS) were upregulated in the renal cortex and outer medulla in response to chronic IL-1␤ infusion. This effect on NOS1 was blunted by A-182086 as determined by post hoc test, whereas A-182086 did not affect NOS3 upregulation. NOS2 (or inducible NOS) was also significantly upregulated by IL-1␤ infusion in all three regions, and this effect was not blunted by A-182086 treatment (Fig. 8) . As shown in Fig. 9A , despite the observed increases in renal NOS mRNA, IL-1␤ infusion had little effect on urinary NO x excretion, producing only a mild increase that did not reach statistical significance (P Infusion ϭ 0.08). Treatment with A-182086 had no effect on urinary NO x excretion (P Antagonist ϭ 0.5; Fig. 9A ). Further supporting a lack of a major role for NO in mediating the diuretic effect of chronic IL-1␤ infusion, urine flow of IL-1␤-infused C57BL/6 mice was not attenuated by treatment with the selective NOS1 inhibitor L-VNIO (Fig. 8B) . Likewise, there was a significant main effect of IL-1␤ infusion to increase urine flow in NOS3 Ϫ/Ϫ mice (P Infusion Ͻ 0.05; Fig. 9C ), and urine flow at day 14 was similar to their corresponding IL-1␤-infused controls.
To give an indication of whether other inflammatory mediators were affected by chronic IL-1␤ infusion, an antibodybased cytokine array analysis of plasma samples was performed. The array contained 40 different cytokines, of which only 7 were significantly different between vehicle-and IL-1␤-infused mice (Fig. 10) .
DISCUSSION
The main finding of the current study is that chronic elevation of IL-1␤ in vivo leads to upregulation of COX-2 expression in the kidney and a COX-2-dependent diuretic response. This diuretic effect occurred independently of the prodiuretic and natriuretic factor ET-1, which was previously found to be upregulated by chronic IL-1␤ infusion (6) and again observed in the current study. Consistent with a primary effect on water transport, a marked decrease in AQP-2 protein expression was observed in the inner medulla of IL-1␤-infused mice, whereas excretion of Na ϩ and K ϩ and expression of NKCC2 were unchanged. The diuresis was accompanied by polydipsia, which was also ameliorated by COX-2 inhibition. Although a primary effect of chronic IL-1␤ on thirst rather than renal function cannot be ruled out, previous studies reported that chronic central administration of IL-1␤ or acute central or peripheral administration of IL-1␤ has either no effect or produces a decrease in water intake by rodents (28, 37, 38) . Together with the observed changes in renal COX-2 and AQP-2 expression, it appears likely that the diuretic response to chronic IL-1␤ is renal in origin.
Acutely, IL-1 (IL-1␣ or IL-1␤) causes natriuresis and diuresis in rats (5, 8, 20) , most likely via inhibitory effects of COX-derived PGE 2 on ion transport at the level of the collecting duct (16, 19, 20, 62) . Acute administration of IL-1␤ has also been shown to reduce mRNA levels of several epithelial transport proteins, including the NKCC2, epithelial Na ϩ channel subunits, Na ϩ -K ϩ -ATPase and NHE3 (47) , and to decrease renal Na ϩ -K ϩ -ATPase protein expression and activity in rats (22) . In contrast to the acute effects of IL-1␤ on the kidney, the predominant effect of chronic IL-1␤ infusion appears to be on water excretion, in association with a marked downregulation of AQP-2 protein levels in the inner medulla, and without a significant effect on Na ϩ excretion. Although interactions between IL-1␤ and vasopressin were not examined in this study, it has previously been shown that IL-1␤ can reduce renal medullary vasopressin V2 receptor binding in vitro (11) , which could potentially translate to reduced AQP-2-mediated water permeability in the collecting duct in vivo. PGE 2 also attenuates the anti-diuretic actions of vasopressin on the collecting duct (31) . In agreement with data presented in the current study, there is evidence from several models that COX-2 activity downregulates AQP-2 levels in vivo. COX-2 inhibition increases AQP-2 expression in lithiuminduced nephrogenic diabetes insipidus (18) , and COX-2 Ϫ/Ϫ mice display increased abundance of AQP-2 and AQP-3 (35) . There is also evidence that prostaglandins and COX-2 activity can decrease NKCC2 expression (9, 18) , which may compromise the cortico-medullary osmotic gradient critical for urine concentration. However, NKCC2 protein expression in the outer medulla was not significantly different between vehicle-and IL-1␤-infused mice in the current study, nor was there any effect on Na ϩ or K ϩ excretion. Accordingly, it is unlikely that the diuretic response to chronic IL-1␤ infusion is mediated via such a mechanism. COX-2 activity has also been shown to contribute to maintenance of medullary blood flow (10). Accordingly, it is possible that COX-2-mediated augmentation of medullary blood flow may also contribute to the diuretic effect of chronic IL-1␤ infusion, but investigation of this mechanism was beyond the scope of the current study.
Despite being once thought of as the inducible form of cyclooxygenase, COX-2 is constitutively expressed in the kidney at several sites, including the macula densa and some cells of the thick ascending limb, as well as renal medullary interstitial cells and collecting duct (15, 61) . Previous studies showed that IL-1␤ stimulates COX-2 production in several cell types in vitro, including renal medullary interstitial cells (7), mesangial cells (40, 41, 44) , and endothelial cells (2) . Proposed mechanisms for this effect of IL-1␤ include increased promoter activation via NF-B, AP-1, ERK, and MAPK pathways (41, 44) , and by stabilization of the 3=-untranslated region of COX-2 mRNA (50). The current study demonstrates that chronic elevation of IL-1␤ in the kidney also increases renal COX-2 expression in vivo, with marked increases in COX-2 mRNA observed in both renal cortex and medulla. Prominent collecting duct staining was observed in the current study, and this appeared to remain the major site of COX-2 immunoreactivity following IL-1␤ infusion. Consistent with previous reports (13, 41) , faint positive staining was also observed in association with cells likely to be renal medullary interstitial cells and glomerular mesangial cells based on their location.
Another novel finding of the current study was that chronic elevation of IL-1␤ increases expression of all three NOS isoforms in the kidney in vivo. All three NOS isoforms are constitutively expressed in the rodent kidney (58) . Although the results of the current study do not support a major role for either NOS1 or NOS3 in mediating the diuretic response to chronic IL-1␤ infusion since urine flow was similarly high in all IL-1␤-infused groups, these isoforms of NOS have been shown to play key roles in the control of tubular transport processes (reviewed in Ref. 30 ). Interestingly, Nakano et al. (32) demonstrated that NOS1 is a key mediator of the effects of ET-1 in the renal medulla, with the diuretic and natriuretic effects of renal medullary ET B receptor stimulation being suppressed by selective NOS1 inhibition. The results of the current study further support a role for ET-1 in regulating NOS1 levels in the kidney, with the IL-1␤-induced increase in renal cortical and outer medullary NOS1 expression appearing to be substantially dependent on ET-1 (see Fig. 8, A and B) . The use of a combined ET A and ET B receptor antagonist in the current study precludes ascribing this effect to one receptor or the other.
Chronic IL-1␤ infusion dramatically upregulated NOS2 mRNA levels within the kidney, particularly in the renal cortex and inner medulla. This effect is consistent with previously reported effects of IL-1␤ to upregulate NOS2 in cultured epithelial cells (55) . Although NOS2 is constitutively expressed in the kidney (1, 58) , its role in regulating renal function is poorly understood and controversial. Interestingly, interactions between IL-1␤, COX-2, NOS2, and prostaglandins have been reported previously in several cell types (reviewed recently in Ref. 42 ). By mechanisms not fully understood, NOS2-derived NO, or perhaps even NOS2 itself, increases COX-2 activity (42). Thus, it is possible that the observed upregulation of NOS2 in the IL-1␤-infused mice may have helped amplify the effects of IL-1␤ on COX-2, thereby contributing indirectly to the diuretic response. In mesangial cells (54), IL-1␤ upregulates both COX-2 and NOS2 enzymes, but COX-2-derived PGE 2 in turn acts as a brake on NOS2 expression, suggesting these systems not only interact in a positive way but also exert reciprocal feedback control. Given the relatively mild change in urinary NO x excretion and the profound effect of COX-2 inhibition on the diuretic response, further investigation of the potential role of NOS2 or its potential interaction with COX-2 in mediating the effects of IL-1␤ was not pursued in the current study, but clearly may be worthy of future consideration.
The findings of the current study may help provide mechanistic insight into several conditions associated with diuresis/ polyuria and defects in urinary concentrating ability. Upregulation of IL-1␤ in the kidney as well as diuresis or a urinary concentrating defect have been reported in acute kidney injury (4, 46) , endotoxemia (11, 47, 60) , and following acute ureteral obstruction (59, 63). Although perhaps not directly correlative with local tissue levels in disease states, it is worth pointing out that the plasma concentrations of IL-1␤ achieved in the current study (ϳ165 pg/ml) are within the range of values reported for such conditions, being greater than in acute kidney injury (20 pg/ml reported in Ref. 17 ) but much lower than in sepsis (Ͼ1,000 pg/ml reported in Ref. 26 ). The mechanisms underlying the concentrating defects and polyuria in these pathological conditions are incompletely understood, but may involve effects on tubular solute and water transporters, as well as hemodynamic effects. A COX-2-dependent downregulation of AQP-2 in the collecting duct and suppression of NKCC2 in the thick ascending limb have been implicated in postobstructive polyuria (33, 34) . Interestingly, lithium-induced nephrogenic diabetes insipidus is also associated with COX-2-mediated dysregulation of AQP-2 in the collecting duct (12), but whether IL-1␤ levels are increased in this condition appears to be unknown. From the results of the current study, it would be interesting to determine whether IL-1␤ serves as a proximal signal to induce COX-2 upregulation and AQP-2 downregulation in these conditions. Deletion of the receptor responsible for IL-1␤ signaling or of other individual cytokines was insufficient to block LPS-induced down-regulation of various tubular ion and urea transport proteins, despite the demonstration that IL-1␤, INF-␥, and TNF-␣ individually can reduce expression of these genes (45) (46) (47) , perhaps indicating some redundancy in severe models of inflammation. Whether IL-1␤ contributes to the downregulation of AQP-2 observed in endotoxemia (11) is unknown, but the results of the current study would suggest this is a distinct possibility. Given the slightly different effects on renal function of acute and chronic IL-1␤ administration noted above, one might ask, do the acute effects of IL-1␤ represent effects of a single cytokine in contrast to chronic administration, which may include induction of other cytokines? The results of the cytokine array depicted in Fig. 10 suggest that chronic IL-1␤ infusion had a systemic proinflammatory effect, but only a relatively small number of proteins were found to be elevated in IL-1␤-infused compared with vehicle-infused mice. The proinflammatory and chemotactic cytokine interleukin-16 (48) was increased by IL-1␤ infusion. IL-1␤ infusion also increased plasma levels of several proteins related to myeloid cells. These include two proteins long known to be regulated by IL-1␤: G-CSF (64) , which promotes the production and maturation of cells including neutrophils and macrophages; and MCP-1 (39), which recruits immune cells such as monocytes, dendritic cells, and T cells to sites of inflammation. IL-1␤ infusion also increased levels of the more recently discovered triggering receptor expressed on myeloid cells 1, which is expressed on myeloid cells and appears to enhance inflammatory responses, and interestingly downregulates the inflammation-limiting IL-1 receptor-associated kinase M (23). IL-1␤ infusion also increased tissue inhibitor of metalloproteinase-1, which has previously been shown to be upregulated by IL-1␤ in inflammatory conditions (56) . In all cases, IL-1␤ has been previously been reported to stimulate production of these molecules. Although some of these cytokines or chemokines have been implicated in renal pathology, particularly MCP-1, whether they could have made a specific contribution to the diuretic effect of chronic IL-1␤ administration is unclear based on the current literature. It also remains unclear as to whether rapid induction or release of other cytokines might contribute to the effects of acute administration of IL-1␤.
In conclusion, this study indicates that chronic elevation of IL-1␤ induces a COX-2-mediated diuretic response in association with marked downregulation of AQP-2 expression in the inner medulla. Several renal pathological conditions are known to be associated with both increased renal expression of IL-1␤ and renal functional abnormalities characterized by diuresis, downregulation of AQP-2, and impaired urinary concentrating abilities. Data from the current study would suggest that IL-1␤ is a promising mediator of renal functional abnormalities in such inflammatory conditions.
